RU2011121388A - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS - Google Patents
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS Download PDFInfo
- Publication number
- RU2011121388A RU2011121388A RU2011121388/15A RU2011121388A RU2011121388A RU 2011121388 A RU2011121388 A RU 2011121388A RU 2011121388/15 A RU2011121388/15 A RU 2011121388/15A RU 2011121388 A RU2011121388 A RU 2011121388A RU 2011121388 A RU2011121388 A RU 2011121388A
- Authority
- RU
- Russia
- Prior art keywords
- rosuvastatin
- composition according
- calcium
- amount
- pharmaceutical composition
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
1. Гиполипидемическая фармацевтическая композиция в виде твердой лекарственной формы, включающая в качестве действующего вещества розувастатин кальция в терапевтически эффективном количестве, и вспомогательные вещества - наполнитель, дезинтегрант, глидант и лубрикант, при этом она не содержит неорганическую соль с поливалентным катионом.2. Композиция по п.1, которая включает в качестве наполнителя модифицированную лактозу.3. Композиция по п.2, которая включает розувастатин кальция в аморфной форме.4. Композиция по п.3, которая выполнена в виде таблетки, покрытой оболочкой.5. Композиция по п.5, которая содержит в единичной дозе розувастатин кальция в количестве 10 мг (в пересчете на розувастатин).6. Композиция по п.5, которая содержит в единичной дозе розувастатин кальция в количестве приблизительно 20 мг (в пересчете на розувастатин).1. A lipid-lowering pharmaceutical composition in the form of a solid dosage form, comprising as active ingredient calcium rosuvastatin in a therapeutically effective amount, and excipients - filler, disintegrant, glidant and lubricant, while it does not contain an inorganic salt with a polyvalent cation. 2. A composition according to claim 1, which comprises modified lactose as a filler. A composition according to claim 2, which comprises calcium rosuvastatin in an amorphous form. The composition according to claim 3, which is made in the form of a coated tablet. The composition according to claim 5, which contains in a single dose of rosuvastatin calcium in an amount of 10 mg (in terms of rosuvastatin). The composition according to claim 5, which contains in a single dose of rosuvastatin calcium in an amount of approximately 20 mg (in terms of rosuvastatin).
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011121388/15A RU2508109C2 (en) | 2011-05-27 | 2011-05-27 | Pharmaceutical composition for treating lipid storage disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011121388/15A RU2508109C2 (en) | 2011-05-27 | 2011-05-27 | Pharmaceutical composition for treating lipid storage disease |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011121388A true RU2011121388A (en) | 2012-12-10 |
RU2508109C2 RU2508109C2 (en) | 2014-02-27 |
Family
ID=49255389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011121388/15A RU2508109C2 (en) | 2011-05-27 | 2011-05-27 | Pharmaceutical composition for treating lipid storage disease |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2508109C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2649811C2 (en) * | 2013-12-18 | 2018-04-04 | Алвоген Кореа Ко, Лтд. | PHARMACEUTICAL COMBINATION PREPARATION CONTAINING THE INHIBITOR OF HMG-CoA REDUCTASE AND INHIBITOR OF CHOLESTEROL ABSORPTION |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
US7241800B2 (en) * | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
-
2011
- 2011-05-27 RU RU2011121388/15A patent/RU2508109C2/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2649811C2 (en) * | 2013-12-18 | 2018-04-04 | Алвоген Кореа Ко, Лтд. | PHARMACEUTICAL COMBINATION PREPARATION CONTAINING THE INHIBITOR OF HMG-CoA REDUCTASE AND INHIBITOR OF CHOLESTEROL ABSORPTION |
Also Published As
Publication number | Publication date |
---|---|
RU2508109C2 (en) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210343T1 (en) | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
RU2014149181A (en) | PYRAZOLE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES | |
WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
JP2012193216A5 (en) | ||
PE20140389A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOFIBROSIS | |
MX2021010046A (en) | A new therapeutical composition containing apomorphine as active ingredient. | |
BR112014014795A2 (en) | immediate release multi-unit pellet system | |
RU2015109566A (en) | NEW EXTRACTS FROM CYNARA SCOLYMUS, COFFEA spp. AND OLEA EUROPAEA FOR THE TREATMENT OF A METABOLIC SYNDROME | |
EA201590142A1 (en) | PHARMACEUTICAL MEDICINE FORMS CONTAINING 5-CHLOR-N - ({(5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) PHENYL] -1,3-OXAZOZOLIDIN-5-IL} METH) -2-TIOFEN-CARBOXAMID | |
MX2019005160A (en) | Pharmaceutical formulation. | |
RU2011121388A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS | |
GR1008228B (en) | Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof | |
JP2012041314A5 (en) | ||
RU2009145804A (en) | AXOMADOL FOR TREATING PAIN FROM ARTHROSIS | |
HRP20211309T1 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
RU2014148062A (en) | INJECTION PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN AND TRAMADOL | |
RU2013105211A (en) | APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS | |
RU2013127794A (en) | PHARMACEUTICAL COMBINATION AND COMPOSITION FOR TREATING OBESITY AND ITS APPLICATION | |
MX2013008996A (en) | Novel pharmaceutical system of biphasic delivery for treating pain and inflammation. | |
HRP20171930T1 (en) | Diazonamide analogs | |
MX2018008443A (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate. | |
RU2013127881A (en) | APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment | |
BR112015030388A2 (en) | pharmaceutical formulation | |
RU2012124232A (en) | PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180528 |